Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18214762 | 0.77 | ATM (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL319902 | 0.77 | MAOB (0.43) | ATMALDH1A1KDM4EALOX15GAA | |
| SCHEMBL16614406 | 0.74 | ATM (0.39) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL30233576 | 0.74 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL25804455 | 0.74 | ATM (0.39) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL25024421 | 0.74 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL77511 | 0.74 | RECQL (0.55) | ATMALDH1A1KDM4EGAAPOLB | |
| SCHEMBL25025784 | 0.74 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL9620230 | 0.74 | ATM (0.39) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL14904407 | 0.73 | ATM (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004011427-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1102535-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1100485-A4 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1313477-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040038982-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| WO-2004010943-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2004011427-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2004010942-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1313477-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1100495-A4 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6399656-B1 | USING A BENZOPYRAN-3-CARBOXAMIDE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-06-04 | — | — | US | disclosed |
| WO-2002005819-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1102535-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1100485-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1100495-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006146-A9 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000006153-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006146-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006085-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038982-A1 | Compounds and methods | CCR5, CXCR3, CCR2 | ATM 2514/4885ALDH1A1 2769/4885KDM4E 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.